Common side effects of beta blockers are nausea , vomiting , abdominal cramps, diarrhea , and weight gain if you are taking medicine for diabetes (type 1 and type 2). There are other important side effects and serious adverse effects of this drug class that include, blurred vision , insomnia , hair loss , disorientation, CNS system effects, and serious heart problems. Beta blockers interact with several other drugs, for example, chlorpromazine ( Thorazine ), clonidine ( Catapres ), Phenobarbital, nonsteroidal anti-inflammatory drugs ( NSAIDs ) including aspirin , and diabetes medications , including insulin .
Adverse effects of lipocryolysis: Analysis of 28 cases
Rafaela Vidal1, Laura Segura2, Paulo Vergara3, Hernán Pinto4
1 IM Clinic, Sant Cugat del Vallès, Spain
2 Policlínico Salud 4, La Coruña, Spain
3 IMEBA, Palma, Spain
4 Instituto de Investigaciones para las Especialidades Estéticas y del Envejecimiento (i2e3), Barcelona, Spain
[email protected] (R. Vidal), [email protected] (L. Segura), [email protected] (P. Vergara), [email protected] (H. Pinto)
To cite this article:
Rafaela Vidal, Laura Segura, Paulo Vergara, Hernán Pinto. Adverse Effects of Lipocryolysis: Analysis of 28 Cases. Journal of Surgery. Special Issue: Breakthroughs in Aesthetic Medicine. Vol. 3, No. 1-1, 2015, pp. 6-7. doi: /
Abstract: Introduction: Lipocryolysis is an effective and safe technique for the treatment of localized adiposities. However, there is very little evidence regarding its adverse effects. Materias and Methods: Retrospective analysis of 28 clinical records.
Results: The adverse effects of lipocryolysis are mild to moderate, and reversible. Discussion: Specific studies need to be carried out in order to survey adverse effects in a large number of subjects, including medium/long-term follow-up.
Keywords: Lipocryolysis, Adverse Effects
ANNA A. SHVEDOVA is Lead Research Physiologist at National Institute for Occupational Safety and Health (NIOSH) at the Center for Disease Control and Prevention (CDC) and Adjunct Professor of the Department of Physiology and Pharmacology, School of Medicine and Adjunct Professor of the Department of Pharmaceutical Sciences, School of Pharmacy of West Virginia University, WV. Dr. Shvedova received her . and . degrees from Moscow University, Russia and is currently Principal Investigator of a number of NORA/National Occupational Research Agenda and NTRC/Nanotechnology Research Center projects at the Exposure Assessment Branch/NIOSH/CDC. Dr. Shvedova was founder and first President of the Dermal Toxicology Specialty Section of the Society of Toxicology (SOT). She is member of advisory board committees for US Army, Air Force and NASA projects and served as workpackage leader in the FP7-NANOMMUNE project (2008-2011), and she is a partner of the FP7-NANOSOLUTIONS project (2011-2017) and member of the ethical board review of the Graphene Flagship Project of the European Commission (2016-2020). Dr. Shvedova has been honored with the SOT Public Communication Award in 2001; Alice Hamilton NIOSH Award for paper of the year in Occupational Safety and Health in 2006, 2009; Bullard-Sherwood Award: Research for Practice in 2011, and Women in Toxicology SOT Award in 2007. Dr. Shvedova is board member of the working group on Skin Notation at NIOSH/CDC, Associate Editor of Toxicology & Applied Pharmacology, and Editorial Board Member of Regulatory Toxicology & Pharmacology. Dr. Shvedova is author or co-author of more than 160 scientific articles and book chapters.